Updated Jul 23, 2007 at 23:4 EST.
In the June 2007 epublication of
Neuropsychopharmacology, MR Safarinejad reviewed the safety of dapoxetine (
Priligy TM
) in a double-blind placebo-based study of men who reported premature ejaculation ( PE ) . In the study 212 men were randomly assigned to either a control group that received a placebo or 30 mg of dapoxetine (
Priligy TM
)
twice daily, twelve weeks for each group. The goal of the study was to increase the intravaginal ejaculatory latency time for men with premature ejaculation ( PE ).
At the beginning of the study, IELT for men in the dapoxetine (
Priligy TM
) group demonstrated a marked increase: 2.9 times over beginning measurements. Men in the control group reported IELT increases of 1.4-fold. The number of intercourse episodes for men in the dapoxetine (
Priligy TM
) group was also higher than men in the placebo group. The dapoxetine (
Priligy TM
) group stopped received the drug after 12 weeks and the effect slowly diminished. The study commented that while men received some benefit from dapoxetine (
Priligy TM
), the effect is not long-term. He recommends further study in order to determine if dapoxetine(
Priligy TM
)
is a viable long-term treatment for premature ejaculation ( PE ).
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
